YU174491A - VACCINES - Google Patents

VACCINES

Info

Publication number
YU174491A
YU174491A YU174491A YU174491A YU174491A YU 174491 A YU174491 A YU 174491A YU 174491 A YU174491 A YU 174491A YU 174491 A YU174491 A YU 174491A YU 174491 A YU174491 A YU 174491A
Authority
YU
Yugoslavia
Prior art keywords
vaccines
immunotherapeutic
mpl
supplemented
preparations
Prior art date
Application number
YU174491A
Other languages
Serbo-Croatian (sh)
Inventor
F. Van Wijhendale
M. Slaoui
C. Bruck
M. Francotte
S. Kummert
Original Assignee
Smit Kline Beesham Biologicals (S.A)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smit Kline Beesham Biologicals (S.A) filed Critical Smit Kline Beesham Biologicals (S.A)
Publication of YU174491A publication Critical patent/YU174491A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

VAKCINE, ovaj pronalazak obezbedjuje nove, suštinski neraskidajuće oblike gp 160, i formulacije vakcine koje sadrže gp 160 ili njegov derivat, dopunjene sa 3-D Mpl. Preparati su korisni za imunoterapeutsko i imunoprofilaktično tretiranje HIV infekcija.VACCINES, this invention provides novel, substantially non-dissolving forms of gp 160, and vaccine formulations containing gp 160 or a derivative thereof, supplemented with 3-D Mpl. The preparations are useful for immunotherapeutic and immunoprophylactic treatment of HIV infections.

YU174491A 1991-03-21 1991-11-01 VACCINES YU174491A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919106048A GB9106048D0 (en) 1991-03-21 1991-03-21 Vaccines

Publications (1)

Publication Number Publication Date
YU174491A true YU174491A (en) 1994-06-10

Family

ID=10691984

Family Applications (1)

Application Number Title Priority Date Filing Date
YU174491A YU174491A (en) 1991-03-21 1991-11-01 VACCINES

Country Status (12)

Country Link
CN (1) CN1064891A (en)
AP (1) AP368A (en)
BR (1) BR9107294A (en)
CZ (1) CZ195793A3 (en)
FI (1) FI934133A (en)
GB (1) GB9106048D0 (en)
HU (2) HU9302642D0 (en)
IL (1) IL99899A0 (en)
MA (1) MA22381A1 (en)
SK (1) SK82593A3 (en)
WO (1) WO1992016556A1 (en)
YU (1) YU174491A (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
US6620414B2 (en) 1992-03-27 2003-09-16 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
SG48309A1 (en) * 1993-03-23 1998-04-17 Smithkline Beecham Biolog Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
GB9706957D0 (en) 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
GB0000891D0 (en) 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
CN1304580C (en) * 2004-07-09 2007-03-14 楼伟 Surface glucoprotein gp160 of recombination expression human acquired immunity defact virus 1
DE602005025647D1 (en) * 2004-07-23 2011-02-10 Novartis Vaccines & Diagnostic POLYPEPTIDES FOR THE OLIGOMERIZATION OF ANTIGENES
EP2305294B1 (en) 2004-09-22 2015-04-01 GlaxoSmithKline Biologicals SA Immunogenic composition for use in vaccination against staphylococcei
WO2008104803A2 (en) 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
EP2447719B1 (en) 2007-02-26 2016-08-24 Oxford BioTherapeutics Ltd Proteins
WO2010084408A2 (en) 2009-01-21 2010-07-29 Oxford Biotherapeutics Ltd. Pta089 protein
WO2011054007A1 (en) 2009-11-02 2011-05-05 Oxford Biotherapeutics Ltd. Ror1 as therapeutic and diagnostic target
SI2726094T1 (en) 2011-06-28 2017-04-26 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
GB201213364D0 (en) 2012-07-27 2012-09-12 Glaxosmithkline Biolog Sa Purification process
GB201213652D0 (en) 2012-08-01 2012-09-12 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
JP2018511655A (en) 2015-03-20 2018-04-26 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Immunogenic compositions for use in vaccination against Bordetella
CN109562057A (en) 2016-05-16 2019-04-02 传染病研究所 Pegylated liposomal and application method
IL314130A (en) 2016-05-16 2024-09-01 Access To Advanced Health Inst Formulation containing tlr agonist and methods of use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89567A0 (en) * 1988-03-28 1989-09-10 Univ Leland Stanford Junior Mutated hiv envelope protein

Also Published As

Publication number Publication date
MA22381A1 (en) 1992-07-01
BR9107294A (en) 1994-06-14
HU9302642D0 (en) 1994-01-28
FI934133A0 (en) 1993-09-21
HUT67011A (en) 1995-01-30
IL99899A0 (en) 1992-08-18
GB9106048D0 (en) 1991-05-08
CN1064891A (en) 1992-09-30
AP9100332A0 (en) 1992-01-31
AP368A (en) 1994-10-28
CZ195793A3 (en) 1994-05-18
SK82593A3 (en) 1994-01-12
FI934133A (en) 1993-09-21
WO1992016556A1 (en) 1992-10-01

Similar Documents

Publication Publication Date Title
YU174491A (en) VACCINES
UA40597C2 (en) Vaccine composition, method for treatment of mammals, diseased or receptive to the infection, method for treatment of mammals with cancer, method for production of vaccine composition, composition of adjuvants
DE69620877D1 (en) DRUG FORMULATIONS FOR IL-12
AU1955088A (en) Avirulent microbes, incapable of producing functional adenylate cyclase and cyclic AMP
TR199802329T2 (en) Use of IL-12 and IFNalpha in the treatment of infectious diseases.
DK1104306T3 (en) Preparations of CpG and Saponin Adjuvants and Methods for Using Them
HUP9801242A1 (en) Hepatitis b vaccine
NO941786L (en) Urethanes and ureas that induce cytokine production
DK0951473T3 (en) Cyclosporin derivative, preparation thereof and pharmaceutical preparations containing this
NL300186I1 (en) Acellular vaccine.
PT97905A (en) METHOD FOR PREPARING PHARMACEUTICAL COMPOSITIONS CONTAINING CISTINE DERIVATIVES
DK0588578T3 (en) immunogens
PT789590E (en) IMMUNOPOTATION INDUCED BY QUITOSAN
EP0830456A4 (en) ISOLATED FrpB NUCLEIC ACID MOLECULE AND VACCINE
GR920100570A (en) 3(2h)-pyridazinone derivatives and process for the preparation thereof.
ATE173628T1 (en) RAPAMYCIN PREPARATIONS FOR ORAL ADMINISTRATION
PT600396E (en) VACCINES AGAINST INTESTINAL PROTOZOARS
WO1992006113A3 (en) Derivatives of gp160 and vaccines based on gp160 or a derivative thereof, containing an adjuvant
ES2159287T3 (en) HEMORREGULATING PEPTIDES.
HU9801705D0 (en) Streptococcus equi vaccine
ATE318300T1 (en) ISOLATED STRAINS OF STAPHYLOCOCCUS AUREUS AND VACCINES PRODUCED THEREFROM
NO933628L (en) Procedure and composition for the treatment of Herpes infections
NO933342L (en) DERIVATIVES OF GP160 AND VACCINES BASED ON GP160 OR A DERIVATIVE THEREOF, CONTAINING AN ADJUVANCE
BG102083A (en) Compositions and methods for the detection and treatment of aids
ES2078380T3 (en) ANTIVIRAL ACTION OLIGOPHOSPHATES.